A Combination Study of Durvalumab plus Olaparib in an Unselected Population with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Abstract
Objective: Increased DNA damage by olaparib will complement the antitumor activity of the immune checkpoint blocking antibody durvalumab. Specific Aims: 1. To determine the response rate of olaparib plus durvalumab in non-DNA damage repair (DDR) mutated mCRPC as measured by PFS and secondarily, as measured by PSA and imaging. 2. To analyze potential biomarkers of response, including genomic, proteomic and immunologic correlates from paired tumor biopsies and blood samples. Impact: Preliminary results from this combination study in an unselected population with mCRPC show robust, sustained PSA findings and objective responses in patients with measurable disease. By using the PD-1/PD-L1 axis as a therapeutic target, in combination with PARP inhibition, regardless of mutational status, we may provide patients a new treatment option. This study may have a broader impact on the development of immunotherapies for all stages of prostate cancer and potentially other immunologically cold tumors. Correlative studies, including genomic and immune assays, will provide preliminary data that can be used to provide information on the mechanism of action and provide data for the development of predictive biomarkers in future studies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2021
- Accession Number
- AD1149962
Entities
People
- Fatima Karzai
Organizations
- Geneva Foundation